The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Michael E. Nassif(Saint Luke's Health System), Mikhail Kosiborod(AstraZeneca (Brazil)), Sanjiv J. Shah(Northwestern University), Sheryl L. Windsor(Saint Luke's Hospital), Sumant Lamba(First Coast Cardiovascular Institute), Gregory D. Lewis(Brigham and Women's Hospital), Susan Joseph(University of Maryland, Baltimore), Barry A. Borlaug(Mayo Clinic), Barry S. Clemson(OSF HealthCare), Michael Pursley(The Heart House), Manreet Kanwar(University of Chicago), Kavita Sharma(Johns Hopkins University), Taiyeb Khumri(Saint Luke's Hospital), Ali O. Malik(Saint Luke's Hospital), Dalane W. Kitzman(Wake Forest University), Guillermo E. Umpierrez(Emory University), Lokesh Chandra, Sunit‐Preet Chaudhry(St. Vincent Hospital), Yevgeniy Khariton(Saint Luke's Hospital), John Ryan(Northwestern University), Sadiya S. Khan(Northwestern University), Fengming Tang(Saint Luke's Hospital), C. Chow(Stormont Vail Health), Michael Fong(University of Southern California), Elias S. Siraj(Eastern Virginia Medical School), Robert Gordon(The University of Texas Health Science Center at Houston)
Cited by 599
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k